Recent Updates
Recently added Catalysts
CBIO Positive Sentiment Score: 75/100

Crescent Biopharma to Present at September Investor Conferences

Key Takeaway: Crescent Biopharma, Inc. has announced its participation in two significant investor conferences scheduled for September 2025. Management will present at the Cantor Global Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference, aiming to raise awareness of its oncology initiatives. The company is focused on delivering next-generation therapies for cancer patients and offers a diverse pipeline that includes innovative treatments. Webcasts of the presentations will be available on their website for investors and interested parties.

Market Sentiment Analysis

POSITIVE FACTORS

  • Crescent Biopharma is presenting at notable investor conferences, highlighting its visibility in the market.
  • The company's pipeline includes promising therapies aimed at treating cancer, indicating strong potential for future growth.

Full Press Release Details

WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September:
Cantor Global Healthcare Conference 2025, fireside chat on Thursday, September 4, 2025, at 1:00 p.m. ET in New York.
Morgan Stanley 23rd Annual Global Healthcare Conference, fireside chat on Monday, September 8, 2025, at 5:35 p.m. ET in New York.
A live webcast of each presentation will be available in the Investors section of the Company's website at https://investors.crescentbiopharma.com/news-events/events, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Chief Communications Officer

Frequently Asked Questions

When is Crescent Biopharma presenting at investor conferences?

Crescent Biopharma will present at the Cantor Global Healthcare Conference on September 4 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025.

Where can I watch Crescent Biopharma's presentations?

Live webcasts of Crescent's presentations will be available in the Investors section of their website.

What is Crescent Biopharma's main focus?

Crescent Biopharma focuses on developing innovative therapies for cancer patients, including a PD-1 x VEGF bispecific antibody.

What types of therapies does Crescent Biopharma offer?

Crescent Biopharma offers bispecific antibodies and novel antibody-drug conjugates aimed at treating solid tumors.

How long will the presentation replays be available?

Replays of the presentations will be accessible for 90 days after the events.

Last updated: Aug 28, 2025